Literature DB >> 28160146

Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus?

A S Kaka1,2,3,4, G A Filice5,6,7,8, M Kuskowski9, D M Musher10,11,12,13.   

Abstract

Infections with Staphylococcus aureus may be more frequent in subjects with active hepatitis C virus (HCV) infection. In this retrospective dual-cohort study, we sought to determine whether persons with active HCV infection (positive HCV antibody, detectable blood HCV RNA) were at greater risk of S. aureus infection than those with spontaneously resolved HCV infection (positive HCV antibody, negative blood HCV RNA). Based on prestudy power calculation, we included 231 subjects with active HCV and 116 subjects with resolved HCV infection. The two groups were well matched at baseline, except that subjects with active HCV had a higher mean Charlson's comorbidity index (2.2 vs. 1.3; p < 0.0001). Cohorts were followed for a mean of 3.67 years. Thirty-one of the 231 (13%) subjects with active HCV infection developed ≥1 S. aureus infection(s) as compared to 4/116 (3.4%) subjects with resolved HCV (p = 0.004), with a trend towards more recurrent S. aureus infections in subjects with active HCV infection. The S. aureus infections were mostly serious, necessitating hospitalization and intravenous antibiotics. In the logistic regression, factors that independently predicted S. aureus infection were active HCV and Charlson's comorbidity index. Our regression models confirmed that the enhanced susceptibility to S. aureus infections was related to active HCV infection and not attributable solely to the increased number of comorbidities [adjusted odds ratio (OR) = 3.3, 95% confidence interval (CI) 1.1-9.8; p = 0.03]. This study shows that subjects with active HCV infection have a significantly higher incidence of serious S. aureus infections than those with spontaneously resolved HCV, even after adjustment for comorbidities.

Entities:  

Mesh:

Year:  2017        PMID: 28160146     DOI: 10.1007/s10096-017-2912-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  A scoring system to differentiate cirrhotic from non-cirrhotic portal hypertension.

Authors:  F P Mistry; D R Karnad; P Abraham; S J Bhatia
Journal:  Indian J Gastroenterol       Date:  1991-07

Review 2.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Peripheral blood count abnormalities among patients with hepatitis C in the United States.

Authors:  Michael B Streiff; Shruti Mehta; David L Thomas
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

Review 4.  Infections due to Staphylococcus aureus.

Authors:  D M Musher; S O McKenzie
Journal:  Medicine (Baltimore)       Date:  1977-09       Impact factor: 1.889

5.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

6.  Increased peroxide production by polymorphonuclear cells of chronic hepatitis C virus-infected patients.

Authors:  F Toro; A Conesa; A Garcia; N E Bianco; J B De Sanctis
Journal:  Clin Immunol Immunopathol       Date:  1998-08

7.  Hepatitis C infection and the risk of bacteremia in hemodialysis patients with tunneled vascular access catheters.

Authors:  Shilpa Reddy; Robert Sullivan; Robert Zaiden; Victor Lopez De Mendoza; Nimish Naik; Kenneth J Vega; N Stanley Nahman; Irene Alexandraki
Journal:  South Med J       Date:  2009-04       Impact factor: 0.954

8.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

9.  Association between hepatitis C infection and other infectious diseases: a case for targeted screening?

Authors:  Hashem B El-Serag; Bhupinderjit Anand; Peter Richardson; Linda Rabeneck
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

10.  Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection.

Authors:  Jonathan Moorman; Zhi P Dong; Lei Ni; Chunlan Zhang; Thomas Borthwick; Zhi Q Yao
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

View more
  4 in total

Review 1.  Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword.

Authors:  Andrew R DiNardo; Mihai G Netea; Daniel M Musher
Journal:  N Engl J Med       Date:  2021-01-21       Impact factor: 91.245

Review 2.  Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections.

Authors:  Sang-Uk Seo; Baik-Lin Seong
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

3.  Computational insight into the protective mechanism of Allium iranicum Wendelbo. Alliaceae in a mouse model of Staphylococcosis: focus on dietary phytocannabinoid trans-caryophyllene.

Authors:  Layth Jasim Mohammed; Khosrow Chehri; Isaac Karimi; Nasser Karimi
Journal:  In Silico Pharmacol       Date:  2021-02-07

4.  Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.

Authors:  Yen-Chieh Lee; Jiun-Ling Wang; Yaa-Hui Dong; Hsi-Chieh Chen; Li-Chiu Wu; Chia-Hsuin Chang
Journal:  PLoS Med       Date:  2019-09-13       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.